Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Iodo-acetamido phenylboronic acid is a synthetic small molecule boronic acid derivative with the molecular formula C8H9BINO3 and a molecular weight of approximately 304.88 g/mol[1][5][7]. It acts as a transition-state analogue inhibitor of class C beta-lactamases, covalently binding to the active-site serine residue (Ser64), thereby inhibiting the enzyme's activity[10]. This compound has been studied primarily in structural biology and enzymology research as an experimental tool to investigate mechanisms of beta-lactamase inhibition and antibiotic resistance[10]. It is not approved for clinical use or marketed as a pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-iodo-acetamido phenylboronic acid.